Drug: Reclast
Generic: Zoledronic acid injection
The company: Novartis ($NVS)
Patent expiration date: March 2, 2013
Estimated Global Sales 2012: $612 million

The scoop: Swiss drugmaker Novartis is bracing itself for a tough few quarters. The company already experienced quite the slump in U.S. sales of its hypertension, heart failure and heart attack drug Diovan since the product's patent expired in September. And 2013 brings more losses; cancer treatment Zometa and osteoporosis treatment Reclast/Aclasta will lose patent protection. Reclast will garner $612 million in estimated sales this year. Novartis is doing what it can to protect its product. In July, the company sued Sun Pharmaceuticals to block it from selling generic forms of Zometa and Reclast. We'll see how that pans out in court.

For more:
Gilenya, Afinitor among bright spots in flat Novartis quarter
FDA panel wants bone drugs' labeling changed, but how?


Suggested Articles

Life sciences companies have pivoted quickly during COVID-19 - Syneos Health® is supporting more than 80 active COVID-19 projects, including vaccines.

New York's Covaxx has signed on with three South American nations to provide 140 million doses of its early-stage COVID-19 vaccine.

To get the COVID-19 vaccine out quickly, Pfizer has been running rehearsals at distribution sites, creating "growing confidence," U.S. officials said.